DSM gut health probiotic strains gets NDI status with no FDA objection

Two strains are Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri 12246-CU.

Two probiotic strains for digestive health from DSM (Parsippany, NJ) have gained new dietary ingredient (NDI) notification status in the U.S., without any objections from FDA. Their new status enables North American dietary supplement companies “to explore new innovations, and ultimately expand their portfolios to cater to the booming gut health trend,” said the company in a press release. The strains are already commercially sold in Europe, Asia, and the Middle East.

Two strains are Lactobacillus rhamnosus 19070-2and Lactobacillus reuteri 12246-CU. “The strains—Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri 12246-CU—demonstrate multiple clinically proven gut-related benefits when combined, including improved digestive comfort and reduced diarrhea,” the company said.

Penny Antonopoulos, director of dietary supplements, Human Nutrition & Care, North America, DSM, added: “The NDI status of our two flagship strains strengthens confidence in our science-based ingredients and creates a multitude of opportunities for our U.S.-based customers to remain at the forefront of the market. Both strains were identified as among the best performing probiotic varieties—out of a total of 47—by a large and comprehensive screening program. Both strains, for example, demonstrated excellent pH tolerance and adhesion properties to enable passage through the gastrointestinal tract and strong antimicrobial activity against pathogenic bacteria. Because of this, the strains were specifically chosen to support customers looking to innovate in the gut health space across a number of applications.”